Related Experiment Videos
Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants
Insights
Indomethacin did not permanently close the patent ductus arteriosus in premature infants. The drug showed prolonged half-lives and impaired platelet function, indicating potential toxicity risks.
Area of Science:
- Neonatal pharmacology
- Pediatric cardiology
Background:
- Patent ductus arteriosus (PDA) is a common condition in premature infants.
- Indomethacin is a commonly used medication to treat PDA.
Observation:
- Indomethacin failed to achieve permanent ductal closure in four premature infants.
- Measured indomethacin half-lives in premature infants were significantly longer (21-24 hours) than in adults or full-term newborns.
- Platelet aggregation was impaired for 2-10 days post-administration.
- One infant experienced gastrointestinal bleeding and transient renal dysfunction.
Findings:
- Indomethacin's efficacy in permanent ductal closure in premature infants is limited.
- Premature infants exhibit prolonged indomethacin half-lives, increasing accumulation risk.
- Significant and prolonged platelet dysfunction occurs after indomethacin administration.
- Indomethacin can cause adverse effects such as gastrointestinal bleeding and renal dysfunction.
Implications:
- Plasma indomethacin concentration monitoring is crucial for dosing and toxicity prevention in sick, low-birthweight infants.
- Further research into indomethacin's toxicity profile is necessary before widespread use for PDA in premature infants.
- Alternative or optimized therapeutic strategies for PDA in premature infants may be required.
Abstract:
Indomethacin failed to produce permanent ductal closure in any of four premature infants with patent ductus arteriosus to whom the drug was given. Indomethacin half-lives measured in two premature infants were 21 and 24 hours, respectively, much longer than in full-term newborns or adults. Platelet function, as measured by platelet aggregation, was grossly abnormal for two to four days after indomethacin administration, normal values returning only by the ninth and tenth days. Gastrointestinal bleeding and transient renal dysfunction occurred in one infant. Measurement of plasma indomethacin concentrations in sick, low-birthweight infants could help guide indomethacin dose and dosage interval, prevent drug accumulation, and reduce toxicity. Further studies of potential toxicity seem to be indicated before instituting widespread indomethacin administration for ductal closure in premature infants.